TY - JOUR
T1 - Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach
AU - Iijima, Katsunori
AU - Abe, Yasuhiko
AU - Kikuchi, Ryosuke
AU - Koike, Tomoyuki
AU - Ohara, Shuichi
AU - Sipponen, Pentti
AU - Shimosegawa, Tooru
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2009/2/21
Y1 - 2009/2/21
N2 - Aim: To study the value of serum biomarker tests to differentiate between patients with healthy or diseased stomach mucosa: i.e. those with Helicobacter pylori (H pylori) gastritis or atrophic gastritis, who have a high risk of gastric cancer or peptic ulcer diseases. Methods: Among 162 Japanese outpatients, pepsinogen I (Pg I) and II (Pg II) were measured using a conventional Japanese technique, and the European GastroPanel examination (Pg I and Pg II, gastrin-17 and H pylori antibodies). Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H pylori non-atrophic gastritis or atrophic gastritis. Results: Pg I and Pg II assays with the GastroPanel and the Japanese method showed a highly significant correlation. For methodological reasons, however, serum Pg I, but not Pg II, was twice as high with the GastroPanel test as with the Japanese test. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis which was also verified by endoscopic biopsies. GastroPanel examination revealed an additional seven patients who had either advanced atrophic gastritis limited to the antrum or antrum-predominant H pylori gastritis. When compared to the endoscopic biopsy findings, the GastroPanel examination classified the patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity. Conclusion: Serum biomarker tests can be used to differentiate between subjects with healthy and diseased gastric mucosa with high accuracy.
AB - Aim: To study the value of serum biomarker tests to differentiate between patients with healthy or diseased stomach mucosa: i.e. those with Helicobacter pylori (H pylori) gastritis or atrophic gastritis, who have a high risk of gastric cancer or peptic ulcer diseases. Methods: Among 162 Japanese outpatients, pepsinogen I (Pg I) and II (Pg II) were measured using a conventional Japanese technique, and the European GastroPanel examination (Pg I and Pg II, gastrin-17 and H pylori antibodies). Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa, H pylori non-atrophic gastritis or atrophic gastritis. Results: Pg I and Pg II assays with the GastroPanel and the Japanese method showed a highly significant correlation. For methodological reasons, however, serum Pg I, but not Pg II, was twice as high with the GastroPanel test as with the Japanese test. The biomarker assays revealed that 5% of subjects had advanced atrophic corpus gastritis which was also verified by endoscopic biopsies. GastroPanel examination revealed an additional seven patients who had either advanced atrophic gastritis limited to the antrum or antrum-predominant H pylori gastritis. When compared to the endoscopic biopsy findings, the GastroPanel examination classified the patients into groups with "healthy" or "diseased" stomach mucosa with 94% accuracy, 95% sensitivity and 93% specificity. Conclusion: Serum biomarker tests can be used to differentiate between subjects with healthy and diseased gastric mucosa with high accuracy.
KW - Gastric atrophy
KW - Helicobacter pylori
KW - Serum gastrin-17
KW - Serum pepsinogen
UR - http://www.scopus.com/inward/record.url?scp=65649150312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65649150312&partnerID=8YFLogxK
U2 - 10.3748/wjg.15.853
DO - 10.3748/wjg.15.853
M3 - Article
C2 - 19230047
AN - SCOPUS:65649150312
VL - 15
SP - 853
EP - 859
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 7
ER -